乌鸦传媒

May become "treatment of choice" over brentuximab vedotin for all disease stages

Likelihood of severe maternal morbidity more than 20 times higher versus the general population

News, features, and commentary about cancer-related issues

Regimen tops best historical response rate with chemoimmunotherapy in this setting

Incidence almost identical to that with standard cancer treatment in randomized trials

Systematic review and meta-analysis finds CAR T-cell-specific toxicities only account for 11.5%

Responses to pirtobrutinib observed in patients with previously treated disease

Better survival in one registry study, detriment with class I HLA mismatch in another

News, features, and commentary about cancer-related issues

News, features, and commentary about cancer-related issues

New iteration of denileukin diftitox led to objective responses in 36% of pretreated patients

News, features, and commentary about cancer-related issues

77% of pregnancies resulted in live births

News, features, and commentary about cancer-related issues